In a report published Tuesday, Morgan Stanley analyst Bin Li reiterated an Overweight rating on Sinovac Biotech Ltd. (NASDAQ: SVA), but removed the $9.00 price target.
In the report, Morgan Stanley noted, “Sinovac's 1Q14 EPS of US$0.00 was above our -US$0.01 estimate on higher hepatitis sales and gross margin. We are pleased to see more tender orders, positive progress of EV71 vaccine and continuous advance of its product pipeline, which should support top-line growth ahead.
1Q14 total sales of US$13.5mn (+34% YoY) topped our forecast by 8% on higher Bilive (Hep A+B vaccine) revenue of US$6.0mn (+100% YoY from US$3mn in 1Q13), partially offset by slower influenza sales of US$61K (vs. our US$0.3mn estimate), as 1H is normally the slowest season for flu vaccines.”
Sinovac Biotech Ltd. closed on Friday at $6.02.
Related Links
-
Morgan Stanley Sees American Express Company As Highest-Probability Bull Case
-
Morgan Stanley Sees Russian Growth Accelerating For Mobile TeleSystems OJSC
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.